Pfizer’s Talzenna combo moves up treatment line with new FDA nod in prostate cancer - Fierce Pharma

Pfizer's Talzenna combination therapy has received a new FDA approval for use in an earlier line of treatment in prostate cancer. The decision moves the combination regimen to an earlier treatment line; the current text does not disclose the specific approved population or trial data.